User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Search

Displaying 3 results.
    • Journal article
    Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
    Eng, Cathy Kim, Tae Won Bendell, Johanna Argilés, Guillem Tebbutt, Niall C Di Bartolomeo, Maria Falcone, Alfredo Fakih, Marwan Kozloff, Mark Segal, Neil H Sobrero, Alberto Yan, Yibing Chang, Ilsung Uyei, Anne Roberts, Louise Ciardiello, Fortunato Ahn, JB Asselah, J Badarinath, S Baijal, S Begbie, S Berry, S Canon, JL Carbone, RG Cervantes, A Cha, YJ Chang, K Chaudhry, A Chmielowska, E Cho, SH Chu, D Couture, F Cultrera, J Cunningham, D Van Cutsem, E Cuyle, PJ Davies, J Dowden, S Dvorkin, M Ganju, V Garcia, RV Kerr, R Kim, TY King, K Kortmansky, J Kozloff, M Lam, KO Lee, J Lee, AS Lesperance, B Luppi, G Ma, B Maiello, E Mandanas, R Marshall, J Marx, G Mullamitha, S Nechaeva, M Park, JO Pavlakis, N Ponce, CG Potemski, P Raouf, S Reeves, J Segal, N Siena, S Smolin, A Streb, JO Strickland, A Szutowicz-Zielinska, E Tabernero, JM Tan, B Valera, JS Van den Eynde, Marc[UCL] Vergauwe, P Vickers, M Womack, M Wroblewska, M Young, R (2019) The Lancet Oncology — Vol. 20, no.6, p. 849-861 (2019)
    • Journal article
    Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Fuchs, Charles S Shitara, Kohei Di Bartolomeo, Maria Lonardi, Sara Al-Batran, Salah-Eddin Van Cutsem, Eric Ilson, David H Alsina, Maria Chau, Ian Lacy, Jill Ducreux, Michel Mendez, Guillermo Ariel Alavez, Alejandro Molina Takahari, Daisuke Mansoor, Wasat Enzinger, Peter C Gorbounova, Vera Wainberg, Zev A Hegewisch-Becker, Susanna Ferry, David Lin, Ji Carlesi, Roberto Das, Mayukh Shah, Manish A RAINFALL Study Group Van den Eynde, Marc[UCL] (2019) The Lancet. Oncology — , p. [1-16] (2019)
    • Speech
    Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study.
    Raghav, Kanwal Pratap Singh Siena, Salvatore Takashima, Atsuo Kato, Takeshi Van den Eynde, Marc[UCL] Di Bartolomeo, Maria Komatsu, Yoshito Kawakami, Hisato Peeters, Marc Andre, Thierry Lonardi, Sara Yamaguchi, Kensei Tie, Jeanne Gravalos Castro, Cristina Strickler, John H Barrios, Daniel Yan, Qi Kamio, Takahiro Kobayashi, Kojiro Yoshino, Takayuki (2023) American Society of ClinicalOncology (ASCO)2023 — McCormick Place, 2301 S King Dr, Chicago, IL 60616, USA